Evidence Explorer · MS-N301 · Botanicals and nutraceuticals · Supportive care · Appraised 11 November 2026
A small double-blind trial found a patient-reported sensory-neuropathy signal after four weeks of low-dose curcumin, without improvement in motor or autonomic domains.
Evidence at a glance
- Evidence label: Preliminary symptom signal; not confirmed
- Benefit: Sensory and total patient-reported neuropathy scores improved versus placebo at day 28; motor and autonomic scores did not.
- Certainty: Low: 70 randomized, 65 completed, short follow-up, mixed cancers and neurotoxic drugs, and no objective neurologic confirmation.
- Risk: Curcumin can cause gastrointestinal effects, interact with medicines and, particularly in enhanced-bioavailability products, has been linked to liver injury.
- Goal: Treatment of established chemotherapy neuropathy symptoms; not tumor response.
What was studied
Design: Seventy adults with neuropathy after platinum agents or paclitaxel were randomized to curcumin 40 mg twice daily or placebo for four weeks; 65 completed the study (31 curcumin, 34 placebo).
Results: At day 28, mean EORTC QLQ-CIPN20 sensory scores were 12.60 versus 15.11 (p=0.021), and the total score also favored curcumin. Motor and autonomic domains were not significantly different. Outcomes were patient-reported.
Identifiers: PMID 42115508; PMCID PMC13332085; registry IRCT20191106045356N6.
What this evidence cannot establish
A four-week change on a symptom questionnaire does not show nerve repair, durable benefit, restored function, improved chemotherapy delivery or cancer control.
The result cannot be generalized to other curcumin products, especially high-bioavailability formulations with different exposure and safety.
Safety and practical context
Turmeric or curcumin can cause nausea, reflux, stomach upset, diarrhea or constipation. Enhanced-bioavailability products have been associated with uncommon liver injury.
Review bleeding risk, gallbladder disease and medicine interactions with the oncology pharmacist.
Questions for the care team
- Does this formulation match the trial product and dose?
- Which symptoms and functional outcomes will be measured, and when would we stop?
- Could this product affect liver tests, bleeding risk or my cancer medicines?
Sources and identifiers
Funding and conflicts: The accessible full-text record was checked; no independent replication was identified. Detailed sponsor and conflict language should be read in the original report.
Source access: Original reports, abstracts/full text where available, registries and authoritative safety sources checked 11 November 2026. Full text was available for the primary trial.
This educational evidence record is not a personal treatment recommendation. Symptom or toxicity findings do not establish tumor response, delayed recurrence or longer survival; laboratory and animal findings are not proof of clinical benefit.
